PubRank

Marc G Ghany

Author PubWeight™ 116.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 9.33
2 Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2008 6.15
3 Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 4.27
4 Current and future therapies for hepatitis C virus infection. N Engl J Med 2013 4.25
5 Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009 3.50
6 Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 3.46
7 Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010 3.35
8 Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007 3.08
9 Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010 2.96
10 Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002 2.64
11 Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005 2.63
12 Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2010 2.47
13 Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008 2.44
14 The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006 2.43
15 Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2009 2.41
16 Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013 2.17
17 Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006 2.06
18 Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005 1.93
19 Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003 1.87
20 Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009 1.80
21 Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2006 1.76
22 Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006 1.73
23 The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013 1.72
24 DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008 1.71
25 Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 2007 1.71
26 Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007 1.70
27 Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005 1.63
28 Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2013 1.63
29 Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010 1.52
30 Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009 1.46
31 Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010 1.43
32 Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2006 1.38
33 A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011 1.33
34 Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012 1.18
35 Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009 1.18
36 Therapy of hepatitis C--back to the future. N Engl J Med 2014 1.17
37 HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006 1.13
38 Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010 1.12
39 Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006 1.08
40 Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009 1.08
41 Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009 1.03
42 S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology 2010 1.03
43 The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2012 1.02
44 Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006 0.99
45 Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008 0.98
46 Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011 0.98
47 Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006 0.96
48 Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology 2007 0.95
49 Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2012 0.94
50 Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006 0.93
51 Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology 2008 0.91
52 A cure for the high cost of hepatitis C virus treatment. Ann Intern Med 2015 0.90
53 A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012 0.90
54 Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2009 0.85
55 The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013 0.85
56 Current and future therapies for hepatitis C virus infection. N Engl J Med 2013 0.84
57 What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 2013 0.83
58 Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am 2010 0.79
59 Hepatitis B virology for clinicians. Clin Liver Dis 2010 0.79
60 Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol 2012 0.78
61 Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex. Ann Intern Med 2007 0.77
62 Assessment of liver fibrosis: palpate, poke or pulse? Hepatology 2005 0.77
63 Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment. Am J Gastroenterol 2010 0.76
64 Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol 2010 0.76
65 Acute hepatitis C: to treat or not to treat. Lancet Infect Dis 2013 0.75
66 Reply: To PMID 23703931. Hepatology 2014 0.75
67 E1 therapeutic vaccination for chronic hepatitis C: all that glitters is not gold. Hepatology 2003 0.75
68 Efforts to define the natural history of chronic hepatitis C continue. Clin Gastroenterol Hepatol 2006 0.75
69 Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. Am J Epidemiol 2017 0.75
70 Management of untreated and nonresponder patients with chronic hepatitis C. Semin Liver Dis 2010 0.75